Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2011

01-10-2011 | Mini Review

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

Author: Kein-Leong Yim

Published in: Endocrine | Issue 2/2011

Login to get access

Abstract

Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody bevacizumab, as well as small molecule inhibitors sunitinib and everolimus.
Literature
1.
S. La Rosa, S. Uccella, G. Finzi, L. Albarello, F. Sessa, C. Capella, Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol. 34, 2–18 (2003)CrossRef
2.
B. Terris, J.Y. Scoazec, L. Rubbia, L. Bregeaud, M.S. Pepper, P. Ruszniewski, J. Belghiti, J. Flejou, C. Degott, Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32, 133–138 (1998)PubMedCrossRef
3.
J. Zhang, Z. Jia, Q. Li, L. Wang, A. Rashid, Z. Zhu, D.B. Evans, J.N. Vauthey, K. Xie, J.C. Yao, Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109, 1478–1486 (2007)PubMedCrossRef
4.
S.R. Silva, K.A. Bowen, P.G. Rychahou, L.N. Jackson, H.L. Weiss, E.Y. Lee, C.M. Townsend Jr, B.M. Evers, VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int. J. Cancer 128, 1045–1056 (2011)
5.
T. Shah, D. Hochhauser, R. Frow, A. Quaglia, A.P. Dhillon, Caplin, M.E.: Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 18, 355–360 (2006)PubMedCrossRef
6.
J.C. Yao, A. Phan, P.M. Hoff, H.X. Chen, C. Charnsangavej, S.C. Yeung, K. Hess, C. Ng, J.L. Abbruzzese, J.A. Ajani, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol. 26, 1316–1323 (2008)PubMedCrossRef
7.
M.H. Kulke, H.J. Lenz, N.J. Meropol, J. Posey, D.P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403–3410 (2008)PubMedCrossRef
8.
E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEJM 364, 501–513 (2011)PubMedCrossRef
9.
T.J. Hobday, J. Rubin, K. Holen, J. Picus, R. Donehower, R. Marschke, W. Maples, R. Lloyd, M. Mahoney, C. Erlichman, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A phase II Consortium (P2C) study. J. Clin. Oncol. 25, abstract 4504 (2007)
10.
I. Duran, J. Kortmansky, D. Singh, H. Hirte, W. Kocha, G. Goss, L. Le, A. Oza, T. Nicklee, J. Ho, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95, 1148–1154 (2006)PubMedCrossRef
11.
J.C. Yao, A.T. Phan, D.Z. Chang, R.A. Wolff, K. Hess, S. Gupta, C. Jacobs, J.E. Mares, A.N. Landgraf, A. Rashid, Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J. Clin. Oncol. 26, 4311–4318 (2008)PubMedCrossRef
12.
J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St.Peter, T. Haas, D. Lebwohl, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J. Clin. Oncol. 28, 69–76 (2010)PubMedCrossRef
13.
J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, Everolimus for advanced pancreatic neuroendocrine tumors. NEJM 354, 514–523 (2011)CrossRef
14.
M.H. Shah, T. Ito, C. Lombard-Bohas, E.M. Wolin, E. Van Cutsem, C. Sachs, R.E. Winkler, J. Lincy, T.J. Hobday, J.C. Yao, Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). J. Clin. Oncol. 29, 158 (2011)CrossRef
15.
J.C. Yao, J.D. Hainsworth, E. Baudin, M. Peeters, D. Hoersch, L.B. Anthony, J. Klimovsky, K. Grouss, V. Jehl, M. Pavel, Everolimus plus octreotide LAR (E + O) versus placebo plus octreotide LAR (P + O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). J Clin Oncol 29, 159 (2011)CrossRef
16.
J.C. Yao, A.T. Phan, D. Fogleman, C.S. Ng, C.B. Jacobs, C.D. Dagohoy, C. Leary, K.R. Hess, Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J. Clin. Oncol. 28, abstract 4002 (2010)
17.
G. Vitale, W.W. de Herder, P.M. van Koetsveld, M. Waaijers, W. Schoordjk, E. Croze, A. Colao, S.W.J. Lamberts, L.J. Hofland, IFN-β is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res. 66(1), 554–562 (2006)PubMedCrossRef
18.
G. Vitale, P.M. van Koetsveld, W.W. de Herder, K. van der Wansem, J.A. Janssen, A. Colao, G. Lombardi, S.W. Lamberts, L.J. Hofland, Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am. J. Physiol. Endocrinol. Metab. 296(3), E559–E566 (2009)PubMedCrossRef
19.
A.W. Tolcher, M.L. Rothenberg, J. Rodon, D. Delbeke, A. Patnaik, L. Nguyen, F. Young, Y. Hwang, C. Haqq, I. Puzanov, Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800–5807 (2009)PubMedCrossRef
20.
D.L. Reidy, E. Hollywood, M. Segal, L. Saltz, A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). ASCO Meeting Abstracts, vol. 28 (2010), p. 4163
21.
L. Kvols, B. Wiedenmann, K. Oberg, J. Glusman, T. O’Dorisio, W. de Herder, B. Gao, R. Arnold, L. Anthony, SOM230 Carcinoid Study Group, Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. ASCO Gastrointestinal Cancers Symposium, Abstract 171, 2006
22.
K.E. Oberg, J.C. Reubi, D.J. Kwekkeboom, E.P. Krenning, Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139(3), 742–753, 753.e1 (2010)
23.
M. Caraglia, M. Marra, P. Tagliaferri, S.W. Lamberts, S. Zappavigna, G. Misso, F. Cavagnini, G. Facchini, A. Abbruzzese, L.J. Hofland, G. Vitale, Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets 9(5), 690–704 (2009)PubMedCrossRef
24.
E. Allen, I.B. Walters, D. Hanahan, Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res. 17(16), 5299–5310 (2011)
25.
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)PubMedCrossRef
26.
P. Therasse, S.G. Arbuck, E.A. Eisenhauer, New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J. Natl. Cancer Inst. 92, 205–216 (2000)PubMedCrossRef
Metadata
Title
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
Author
Kein-Leong Yim
Publication date
01-10-2011
Publisher
Springer US
Published in
Endocrine / Issue 2/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9513-y

Other articles of this Issue 2/2011

Endocrine 2/2011 Go to the issue

Letter to the Editor

A rare case of resistance to thyroid hormone coexisting with Graves’ disease

Review

Do we really know why diabetes remits after gastric bypass surgery?

Original Article

Ghrelin reduces voltage-gated calcium currents in GH3 cells via cyclic GMP pathways

Original Article

Factor analysis of modifiable cardiovascular risk factors and prevalence of metabolic syndrome in adult Taiwanese

Original Article

Elevated serum γ-glutamyltransferase predicts the development of impaired glucose metabolism in middle-aged and elderly Chinese

Original Article

Evaluation of the effect of l-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits